Illumina, Inc. $ILMN Holdings Lifted by Cwm LLC

Cwm LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 22.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 135,535 shares of the life sciences company’s stock after purchasing an additional 25,160 shares during the period. Cwm LLC’s holdings in Illumina were worth $17,777,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. grew its position in Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after purchasing an additional 124,246 shares during the last quarter. Generali Asset Management SPA SGR grew its position in Illumina by 51.6% in the 3rd quarter. Generali Asset Management SPA SGR now owns 22,249 shares of the life sciences company’s stock worth $2,113,000 after purchasing an additional 7,574 shares during the last quarter. Elo Mutual Pension Insurance Co bought a new position in Illumina in the 3rd quarter worth about $2,319,000. Douglas Lane & Associates LLC grew its position in Illumina by 6.6% in the 3rd quarter. Douglas Lane & Associates LLC now owns 307,609 shares of the life sciences company’s stock worth $29,214,000 after purchasing an additional 18,914 shares during the last quarter. Finally, Caprock Group LLC acquired a new stake in shares of Illumina in the 3rd quarter worth approximately $1,479,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 1.3%

ILMN stock opened at $134.50 on Friday. Illumina, Inc. has a 12 month low of $69.83 and a 12 month high of $155.53. The firm has a market cap of $20.43 billion, a PE ratio of 24.68, a P/E/G ratio of 2.55 and a beta of 1.49. The firm has a 50 day simple moving average of $123.81 and a 200 day simple moving average of $124.58. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Illumina from $130.00 to $120.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Guggenheim upped their price target on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Stifel Nicolaus upped their price target on shares of Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Piper Sandler reduced their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $129.69.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the sale, the senior vice president owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.60% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.